Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Abi Vijenthira, MD, Manjula Mangati, Michael Crump, MD, Vishal Kukreti, MD, John Kuruvilla, MD, Rodger Tiedemann, MD PhD, Christine Chen, MD, Anca Prica, MD

Blood (2016) 128 (22): 1795.

https://doi.org/10.1182/blood.V128.22.1795.1795

Published: 2016

Journal Articles

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Anca Prica, MD, Vinita Dhir, Nuchanan Areethamsirikul, MD, Christine Chen, MD, Donna Reece, MD, Suzanne Trudel, MD, Rodger Tiedemann, MBChB, PhD, Vishal Kukreti, MD

Blood (2016) 128 (22): 1184.

https://doi.org/10.1182/blood.V128.22.1184.1184

Published: 2016

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 3457.

https://doi.org/10.1182/blood.V128.22.3457.3457

Published: 2016

Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2016) 128 (22): 2137.

https://doi.org/10.1182/blood.V128.22.2137.2137

Published: 2016

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite TMÂ chain (HLC) Normalization

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhDMSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Prica Anca, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul

Blood (2015) 126 (23): 1982.

https://doi.org/10.1182/blood.V126.23.1982.1982

Published: 2015

Journal Articles

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Sara Farshchi-Zarabi, MD, Gurdeep Parmar, MD, Esther Masih-Khan, PhD, Sophia Farooki, MD FRCPC, Christine Chen, MD FRCPC, Vishal Kukreti, MD FRCPC, Anca Prica, MD FRCPC, Rodger Tiedemann, MBChB, FRCPC, PhD, Suzanne Trudel, MD, Donna Reece

Blood (2015) 126 (23): 3176.

https://doi.org/10.1182/blood.V126.23.3176.3176

Published: 2015

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Majed Alahmadi, MBBS, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Limore Arones, Christine Chen, MD, Vishal Kukreti, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD, Donna Reece

Blood (2015) 126 (23): 1842.

https://doi.org/10.1182/blood.V126.23.1842.1842

Published: 2015

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Bethany E Monteith, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Christine Chen, MD, Anca Prica, MD, Donna Reece, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2015) 126 (23): 5361.

https://doi.org/10.1182/blood.V126.23.5361.5361

Published: 2015

Journal Articles

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Christopher P. Venner, MD, Darrell White, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD

Blood (2014) 124 (21): 3990.

https://doi.org/10.1182/blood.V124.21.3990.3990

Published: 2014

Journal Articles

GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

Suzanne Trudel, MD, Sam Scanga, PhD, Fabrizio G Mastronardi, PhD, Ellen Nong Wei, MSc, Frank Mercurio, PhD, Antonia Lopez-Girona, PhD, Svetlana Gaidarova, MS, David R. Webb, PhD, Christine Chen, MD, Keith Stewart, MBA, MB, CHB, Armen S Manoukian, PhD

Blood (2012) 120 (21): 1793.

https://doi.org/10.1182/blood.V120.21.1793.1793

Published: 2012

Journal Articles

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Christine Chen, MD, Harminder Paul, Trina Wang, RN, Lisa W Le, MSc, Vishal Kukreti, MD, Ellen Nong Wei, Anthea Lau, P. Leif Bergsagel, MD, Nimisha Dave, Suzanne Trudel, MD

Blood (2012) 120 (21): 718.

https://doi.org/10.1182/blood.V120.21.718.718

Published: 2012

Journal Articles

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Christine Chen, MD, Harminder Paul, Luisa Del Rizzo, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B Gibson, PhD, Michelle Brown, Suzanne Trudel, MD

Blood (2012) 120 (21): 2895.

https://doi.org/10.1182/blood.V120.21.2895.2895

Published: 2012

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

Journal Articles

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Christine Chen, MD, MEd, FRCPC, Ahmed M. Rabea, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Vishal Kukreti, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 3983.

https://doi.org/10.1182/blood.V118.21.3983.3983

Published: 2011

NARROW

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only